WO2016180848A1 - Soft capsule and use in the treatment of halitosis - Google Patents

Soft capsule and use in the treatment of halitosis Download PDF

Info

Publication number
WO2016180848A1
WO2016180848A1 PCT/EP2016/060492 EP2016060492W WO2016180848A1 WO 2016180848 A1 WO2016180848 A1 WO 2016180848A1 EP 2016060492 W EP2016060492 W EP 2016060492W WO 2016180848 A1 WO2016180848 A1 WO 2016180848A1
Authority
WO
WIPO (PCT)
Prior art keywords
soft capsule
extract
harmful bacteria
stomach
blocking adhesion
Prior art date
Application number
PCT/EP2016/060492
Other languages
English (en)
French (fr)
Inventor
Robin List
Original Assignee
Sylphar Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sylphar Nv filed Critical Sylphar Nv
Priority to EP16725783.1A priority Critical patent/EP3294271B1/en
Publication of WO2016180848A1 publication Critical patent/WO2016180848A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/185—Vegetable proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
    • A23P10/00—Shaping or working of foodstuffs characterised by the products
    • A23P10/30—Encapsulation of particles, e.g. foodstuff additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733—Fructosans, e.g. inulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/734—Alginic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/11—Encapsulated compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/92—Oral administration

Definitions

  • the invention is broadly in the medical field, more precisely in the field of dietary supplements useful for the treatment of halitosis.
  • the invention concerns a soft capsule and its use in the treatment of halitosis.
  • Breath malodour also referred to as halitosis
  • halitosis is a significant social and psychological handicap. Up to 50% of the population can suffer from oral malodour. The causes and intensity of the oral malodour may vary.
  • the primary origin of halitosis is the result of microbial putrefaction accompanied by the release of volatile sulphur compounds (VSCs), for instance hydrogen sulphide (H 2 S), methyl mercaptan (CH 3 SH), and dimethyl sulphide (CH 3 ) 2 S, and other volatile compounds such as butyric or propionic acid, and diamines.
  • VSCs volatile sulphur compounds
  • H 2 S hydrogen sulphide
  • CH 3 SH methyl mercaptan
  • CH 3 ) 2 S dimethyl sulphide
  • other volatile compounds such as butyric or propionic acid, and diamines.
  • the causes of halitosis may be exogenous and may relate to lack of saliva flow while sleeping, consumption of certain foods such as garlic and onion, consumption of certain drinks such as alcohol and dairy products, and/or smoking.
  • the causes of halitosis may also be endogenous in which case the halitosis is also referred to as true oral halitosis.
  • True oral halitosis can be related to disorders of the oral cavity such as poor oral hygiene or gingivitis; disorders of the respiratory tract; disorders of gastrointestinal (GI) tract, or to drugs. Halitosis may also have psychogenic causes.
  • mouthrinses comprise antimicrobial agents such as chlorhexidine and cetylpyridinium chloride (CPC).
  • CPC cetylpyridinium chloride
  • the present inventors have found pharmaceutical formulations, in particular soft capsules, addressing one or more of the above-mentioned problems in the art.
  • a first aspect of the invention relates to a soft capsule (i.e., capsule- in-capsule) comprising (a) a first soft capsule configured for targeted delivery to the mouth and (b) a second soft capsule configured for targeted delivery to the stomach, wherein the first soft capsule comprises one or more active ingredients capable of blocking adhesion of harmful bacteria to the oral cavity, a metal salt, and a prebiotic fibre, wherein the one or more active ingredients capable of blocking adhesion of harmful bacteria to the oral cavity are selected from the group consisting of cranberry extract, wild blueberry extract, strawberry extract, tea tree oil, and chamomile oil, and wherein the metal salt is a zinc salt; the second soft capsule comprises one or more active ingredients capable of blocking adhesion of harmful bacteria to the stomach and an alginate, wherein the one or more active ingredients capable of blocking adhesion of harmful bacteria to the stomach are selected from the group consisting of cranberry extract, wild blueberry extract, strawberry extract, tea tree oil, chamomile oil, tea extract, nee
  • Such soft capsules advantageously allow a targeted and sustained therapeutic delivery of the active ingredients in the mouth followed by a targeted and therapeutic delivery of the active ingredients in the stomach, thereby allowing an effective instant and long-term treatment of halitosis.
  • the soft capsules illustrating the principles of the present invention allow an instant effect and a long-term effect by treatment of halitosis in the mouth and in the gastrointestinal tract, in particular in the stomach. These effects are obtained without the side effects of currently available OTC drugs.
  • the active ingredients in the first soft capsule effectively allow neutralization of undesired bacteria and provide prebiotic stimulation of good oral microflora, without any side effects such as dental discoloration.
  • the active ingredients in the second soft capsule also effectively allow neutralization of undesired bacteria and form a protective layer on top of the stomach content, thereby inhibiting gastric reflux.
  • a second aspect relates to the soft capsules as taught herein, for use as a medicament.
  • a further aspect relates to the soft capsules as taught herein, for use in the treatment of halitosis, preferably wherein the treatment comprises an oral treatment of halitosis and a gastrointestinal treatment of halitosis.
  • a further aspect relates to a method for preparing the soft capsules as taught herein, comprising simultaneously extruding a composite jet stream into a cooling solution, wherein the composite jet stream consists of a second soft capsule filling solution extruded through a first nozzle, a second soft capsule layer-forming solution though a second nozzle, a first soft capsule filling solution extruded through a third nozzle and a first soft capsule layer-forming solution extruded through a fourth nozzle, with the first, second, third and fourth nozzles being arranged concentrically, a diameter of the nozzles gradually increasing in a numerical order, and wherein the first soft capsule layer-forming solution comprises a metal salt, wherein the metal salt is a zinc salt; the first soft capsule filling solution comprises one or more active ingredients capable of blocking adhesion of harmful bacteria to the oral cavity and a prebiotic fibre, wherein the one or more active ingredients capable of blocking adhesion of harmful bacteria to the oral cavity are selected from the group consisting of cranberry extract, wild
  • the term "one or more”, such as one or more members of a group of members, is clear per se, by means of further exemplification, the term encompasses inter alia a reference to any one of said members, or to any two or more of said members, such as, e.g., any >3, >4, >5, >6 or >7 etc. of said members, and up to all said members.
  • the present inventors have found a therapeutic composition comprising a unique combination of active ingredients to effectively treat and prevent halitosis.
  • the therapeutic composition is formulated in a soft capsule.
  • a first aspect of the invention relates to a soft capsule comprising (a) a first soft capsule configured for targeted delivery to the mouth and (b) a second soft capsule configured for targeted delivery to the gastrointestinal tract, in particular to the stomach, wherein the first soft capsule comprises an active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity, a metal salt, and a prebiotic fibre; the second soft capsule comprises an active ingredient capable of blocking adhesion of harmful bacteria to the stomach and an alginate; and the second soft capsule is contained in the first soft capsule.
  • the invention relates to a soft capsule comprising (a) a first soft capsule configured for targeted delivery to the mouth and (b) a second soft capsule configured for targeted delivery to the stomach, wherein the first soft capsule comprises one or more active ingredients capable of blocking adhesion of harmful bacteria to the oral cavity, a metal salt, and a prebiotic fibre, wherein the one or more active ingredients capable of blocking adhesion of harmful bacteria to the oral cavity are selected from the group consisting of cranberry extract, wild blueberry extract, strawberry extract, tea tree oil, and chamomile oil, and wherein the metal salt is a zinc salt; the second soft capsule comprises one or more active ingredients capable of blocking adhesion of harmful bacteria to the stomach and an alginate, wherein the one or more active ingredients capable of blocking adhesion of harmful bacteria to the stomach are selected from the group consisting of cranberry extract, wild blueberry extract, strawberry extract, tea tree oil, chamomile oil, tea extract, neem stick extract, snowdrop extract, seaweed extract, hop bract extract,
  • the soft capsule as taught herein comprises a first soft capsule configured for targeted delivery to the mouth (i.e., outer capsule) and a second soft capsule configured for targeted delivery to the stomach (i.e., inner capsule), wherein the second soft capsule is contained in the first soft capsule.
  • the first soft capsule as taught herein is configured for targeted delivery to the mouth.
  • the recitation "configured for targeted delivery to the mouth” as used herein refers to the capability of the first soft capsule to be soluble in the oral cavity.
  • the solubility of the first soft capsule advantageously allows releasing the active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity, the metal salt, and the prebiotic fibre in the oral cavity.
  • the first soft capsule as taught herein may be dissolved in the oral cavity by masticating the first soft capsule and/or by contacting or mixing the first soft capsule with saliva. In certain embodiments, the first soft capsule as taught herein opens in the oral cavity, thereby advantageously releasing the active ingredients having an effect in the oral cavity.
  • the second soft capsule as taught herein is configured for targeted delivery to the stomach.
  • the recitation "configured for targeted delivery to the stomach” as used herein refers to the capability of the second soft capsule to be soluble in a stomach.
  • the solubility of the second soft capsule advantageously allows releasing the active ingredient capable of blocking adhesion of harmful bacteria to the stomach and an alginate in the stomach.
  • the second soft capsule as taught herein may be dissolved in the gastrointestinal tract, in particular in the stomach, by contacting the second soft capsule with gastric acid.
  • the second soft capsule as taught herein opens in the stomach, thereby advantageously releasing the active ingredients having an effect in the stomach.
  • the second soft capsule as taught herein may not be soluble in the oral cavity. In certain embodiments, the second soft capsule as taught herein may not be dissolved in the oral cavity by masticating the second soft capsule and/or by contacting or mixing the second soft capsule with saliva. Usually, once the first soft capsule has dissolved in the oral cavity, the remaining second soft capsule will be swallowed by the subject (due to the size of the second soft capsule).
  • oral cavity or “mouth” can be used interchangeably and generally refer to the first portion of the alimentary canal that receives food and saliva.
  • the inside of the mouth is lined with a mucous membrane, the oral mucosa.
  • the term "stomach” generally refers to the part of the digestive system located between the oesophagus and the small intestine which functions as an important organ of the digestive tract. It is involved in the second phase of digestion, following mastication (i.e., chewing). Like the other parts of the gastrointestinal tract, the stomach wall is lined with mucosa.
  • the present soft capsule comprising (a) a first soft capsule configured for targeted delivery to the mouth and (b) a second soft capsule configured for targeted delivery to the stomach has two effects of eliminating bad breath or treating halitosis, including an immediate effect and a long-lasting effect, by administration, preferably oral administration, of one capsule.
  • the active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity, the metal salt, and the prebiotic fibre, which are contained in the first soft capsule, can immediately eliminate the odour after oral administration and allow stimulating the growth and/or activity of beneficial bacteria, thereby contributing to the long-lasting effect of treating halitosis.
  • the first soft capsule may also contain a flavouring component so that a bitter flavour is sweetened when the capsule is dissolved and masticated in the oral cavity, and therefore, the soft capsule has excellent palatability.
  • the second soft capsule comprising the active ingredient capable of blocking adhesion of harmful bacteria to the stomach and the alginate, reaches the stomach without dissolving and masticating in the oral cavity, as well as without mixing with saliva or other peptic juice, and then dissolves in a stomach to show an effect of eliminating "returned odour" and to neutralize harmful bacteria in the stomach.
  • the active ingredients as taught herein are formulated in a soft capsule.
  • soft capsule or “soft-shelled capsule” can be used interchangeably and typically refer to a solid dosage form in which the active ingredient(s) is (are) enclosed in a soft container or shell.
  • the soft container or shell is typically made of a material capable of forming a soft capsule such as gelatine, agar, methylcellulose, hypromellose or hydroxypropylmethylcellulose (HPMC), or a mixture of any two or more thereof.
  • active ingredient or “active component” can be used interchangeably and broadly refer to a compound or substance which, when provided in an effective amount, achieves a desired therapeutic and/or prophylactic outcome(s). Typically, an active ingredient may achieve such outcome(s) through interacting with and/or modulating living cells or organisms.
  • active in the recitations "active ingredient” or “active component” refers to “pharmacologically active” and/or “physically active”.
  • the first soft capsule as taught herein comprises an active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity (e.g., to oral tissue such as the oral mucosa), a metal salt, and a prebiotic fibre.
  • the active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity in the first soft capsule as taught herein advantageously neutralizes harmful bacteria in the mouth.
  • the active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity adheres to the harmful bacteria without destroying them, thereby blocking bacterial adhesion to the oral mucosa while advantageously preserving immunogenicity.
  • the natural immune system of the subject can react to the harmful bacteria, thereby allowing that the subject develops immunity.
  • the metal salt in the first soft capsule as taught herein advantageously allows eliminating volatile malodour gases by capturing Volatile Sulphur Compounds (VSCs) such as methyl mercaptan produced by harmful bacteria or food.
  • VSCs Volatile Sulphur Compounds
  • the prebiotic fibre in the first soft capsule as taught herein advantageously optimizes the oral microflora by selectively stimulating the growth and/or activity of beneficial bacteria.
  • the prebiotic fibre advantageously allows reducing the proliferation of harmful bacteria.
  • the active ingredients in the first soft capsule as taught herein allow immediate and long-term effective treatment and/or prevention of halitosis in a subject
  • the second soft capsule as taught herein comprises an active ingredient capable of blocking adhesion of harmful bacteria to the stomach and an alginate.
  • the active ingredient capable of blocking adhesion of harmful bacteria to the stomach in the second soft capsule as taught herein advantageously neutralizes harmful bacteria in the stomach.
  • the active ingredient capable of blocking adhesion of harmful bacteria to the stomach adheres to the harmful bacteria such as Helicobacter pylori without destroying them, thereby blocking bacterial adhesion to the mucosa of the stomach while advantageously preserving immunogenicity.
  • the natural immune system of the subject can react to the harmful bacteria such as Helicobacter pylori, thereby allowing that the subject develops immunity.
  • the alginate in the second soft capsule as taught herein allows the formation of a protective layer on the top of the stomach, thereby suppressing gastro-oesophageal reflux and preventing the reflux of gastric acids.
  • the active ingredients in the second soft capsule as taught herein allow immediate and long-term effective treatment and/or prevention of halitosis in a subject.
  • the first soft capsule may comprise, consist essentially of, or consist of the active ingredients having an effect in the oral cavity. In certain embodiments, the first soft capsule may comprise, consist essentially of, or consist of an active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity, a metal salt, and a prebiotic fibre.
  • the phrase "an active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity” includes the wording "one or more active ingredients capable of blocking adhesion of harmful bacteria to the oral cavity". Accordingly, in certain embodiments, the first soft capsule may comprise, consist essentially of, or consist of one or more active ingredients capable of blocking adhesion of harmful bacteria to the oral cavity, a metal salt, and a prebiotic fibre.
  • the one or more active ingredients such as two or more, or three or more, or four or more active ingredients, capable of blocking adhesion of harmful bacteria to the oral cavity or to the stomach may be selected from the group consisting of cranberry extract, wild blueberry extract, strawberry extract, tea tree oil, chamomile oil, tea extract, neem stick extract, snowdrop extract, seaweed extract, hop bract extract, Galla chinensis extract, avocado, and legume storage proteins.
  • the one or more active ingredients capable of blocking adhesion of harmful bacteria to the oral cavity or to the stomach may be selected from the group consisting of cranberry extract, (wild) blueberry extract, or strawberry extract. These extracts advantageously allow neutralizing harmful bacteria in the oral cavity and in the stomach. Such extracts adhere to the harmful bacteria without destroying them, thereby blocking bacterial adhesion to the mouth tissue (e.g., oral mucosa) or stomach tissue (e.g., stomach mucosa) while advantageously allowing immunogenicity.
  • the one or more active ingredients capable of blocking adhesion of harmful bacteria to the oral cavity or to the stomach may be selected from the group consisting of cranberry extract, wild blueberry extract, strawberry extract, tea tree oil, and chamomile oil. In certain embodiments, the one or more active ingredients capable of blocking adhesion of harmful bacteria to the oral cavity or to the stomach may be selected from the group consisting of cranberry extract, tea tree oil, and chamomile oil.
  • the one or more active ingredients capable of blocking adhesion of harmful bacteria to the oral cavity or to the stomach may be cranberry extract and tea tree oil. In certain embodiments, the one or more active ingredients capable of blocking adhesion of harmful bacteria to the oral cavity or to the stomach may be cranberry extract and chamomile oil. In certain embodiments, the one or more active ingredients capable of blocking adhesion of harmful bacteria to the oral cavity or to the stomach may be tea tree oil and chamomile oil. In certain embodiments, the one or more active ingredients capable of blocking adhesion of harmful bacteria to the oral cavity or to the stomach may be cranberry extract, tea tree oil, and chamomile oil.
  • the active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity or to the stomach may be cranberry extract.
  • the active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity or to the stomach may be tea tree oil.
  • the active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity or to the stomach may be chamomile oil.
  • the active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity or to the stomach may be selected from the group consisting of cranberry extract, tea extract, neem stick extract, snowdrop extract, seaweed extract, hop bract extract, Galla chinensis extract, avocado, and legume storage proteins.
  • the active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity or to the stomach may be selected from the group consisting of cranberry (Vaccinium macrocarpori) extract, green tea (Camillia sinensis) extract, oolong tea extract, neem stick (Azadirachta indica) extract, snowdrop (Gilanthus nivalis) extract, seaweed (Gloipeltis furcata) extract, seaweed (Gigartine teldi) extract, hop bract or leaves extract, Galla chinensis extract, avocado (Persea Americana), and a legume storage protein.
  • cranberry Vaccinium macrocarpori
  • green tea Camillia sinensis
  • oolong tea extract neem stick
  • neem stick Azadirachta indica
  • snowdrop Gilanthus nivalis
  • seaweed Gloipeltis furcata
  • seaweed seaweed
  • the active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity or to the stomach is cranberry extract.
  • Cranberry extract advantageously allows neutralizing harmful bacteria in the oral cavity and in the stomach. Cranberry extract adheres to the harmful bacteria without destroying them, thereby blocking bacterial adhesion to the mouth tissue (e.g., oral mucosa) or stomach tissue (e.g., stomach mucosa) while advantageously allowing immunogenicity.
  • Cranberry extract is rich in proanthocyanidins (PACs).
  • Proanthocyanidins also known as oligomeric proanthocyanidins (OPC), pycnogenol, leukocyanidins, or leucoanthocyanins, are a class of polyphenols found in a variety of plants. Chemically, proanthocyanidins are oligomeric flavonoids.
  • the concentration of the proanthocyanidins in the cranberry extract is from 5 ⁇ g/ml to 100 ⁇ g/ml.
  • Cranberry extract is commercially available for example as ExocyanTM Cran 70S (Nexira, Rouen Cedex, France).
  • the active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity or to the stomach may be wild blueberry extract or strawberry extract. Wild blueberry extract and strawberry extract are rich in polyphenols.
  • the active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity or to the stomach may be tea tree ⁇ Melaleuca alternifolia) oil.
  • Tea tree oil advantageously allows neutralizing harmful bacteria in the oral cavity and in the stomach.
  • Tea tree oil is defined by the International Standard ISO 4730 ("Oil of Melaleuca, Terpinen-4-ol type"), which specifies levels of 15 components which define the oil as "tea tree oil”.
  • the active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity or to the stomach may be chamomile oil.
  • Chamomile oil advantageously allows neutralizing harmful bacteria in the oral cavity and in the stomach.
  • the active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity or to the stomach is tea extract.
  • the tea extract may be extract of green tea (Camillia sinensis) or extract of oolong tea.
  • Green tea extract is rich in (-) epicatechin gallate and (-) gallocatechin gallate.
  • Oolong tea extract is rich in polyphenols.
  • Green tea extract is commercially available for example as green tea extract 95% (Product No. P07361, Cambridge Commodities Ltd., Cambridgeshire, UK) or green tea extract 98%> (Product No. P07389, Cambridge Commodities Ltd., Cambridgeshire, UK).
  • the active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity or to the stomach is Galla chinensis extract.
  • Galla chinensis extract refers to extract of galls produced on the Chinese sumac (Rhus chinensis) by the Chinese sumac aphid, also known as Schlectendalia chinensis or Melaphis chinensis.
  • Galla chinensis extract is rich in gallotannins, a type of hydrolysable tannins.
  • the active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity or to the stomach is a legume storage protein.
  • legume storage proteins are present in seeds, particularly of leguminous plants.
  • Legume storage proteins contain glycoproteins.
  • the first soft capsule may comprise the active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity, such as a cranberry extract, in an amount of 1 to 90 parts by weight based on 100 parts by weight of the first soft capsule.
  • the first soft capsule may comprise the active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity, such as a cranberry extract, in an amount of 1 to 75 parts by weight, 1 to 50 parts by weight, 1 to 25 parts by weight, 1 to 10 parts by weight, or 1 to 5 parts by weight based on 100 parts by weight of the first soft capsule.
  • the second soft capsule may comprise the active ingredient capable of blocking adhesion of harmful bacteria to the stomach, such as a cranberry extract, in an amount of 1 to 90 parts by weight based on 100 parts by weight of the second soft capsule.
  • the second soft capsule may comprise the active ingredient capable of blocking adhesion of harmful bacteria to the stomach, such as a cranberry extract, in an amount of 1 to 75 parts by weight, 1 to 50 parts by weight, 1 to 25 parts by weight, or 1 to 10 parts by weight based on 100 parts by weight of the second soft capsule.
  • the metal salt may be selected from the group consisting of a zinc salt, a lead salt, a copper salt, a mercury salt, a cadmium salt, and a tin salt; preferably wherein the metal salt is a zinc salt.
  • a zinc salt in the first soft capsule as taught herein advantageously allows eliminating volatile malodour gases by capturing VSCs such as methyl mercaptan.
  • the metal salt may be a zinc salt selected from the group consisting of zinc acetate, zinc gluconate, zinc picolinate, zinc amino acid chelate, zinc chloride, zinc citrate, zinc bisglycinate chelate, zinc stearate, zinc lactate, zinc ammonium sulfate, zinc chromate, zinc dithionate, zinc fluorosilicate, zinc tartrate, zinc formate, zinc iodide, zinc nitrate, zinc phenol sulfonate, zinc salicylate, zinc sulfate, zinc succinate, zinc glycerophosphate, and zinc halides.
  • the metal salt may be a zinc salt selected from the group consisting of zinc acetate, zinc gluconate, zinc picolinate, zinc amino acid chelate, zinc chloride, zinc citrate, and zinc bisglycinate chelate.
  • the metal salt is zinc acetate.
  • the first soft capsule may comprise the zinc salt, such as zinc acetate, in an amount of 0.01 to 10 parts by weight based on 100 parts by weight of the first soft capsule.
  • the first soft capsule may comprise the zinc salt, such as zinc acetate, in an amount of 0.01 to 5 parts by weight, 0.05 to 5 parts by weight, 0.1 to 2 parts by weight, 0.1 to 1 parts by weight, or 0.1 to 0.5 parts by weight based on 100 parts by weight of the first soft capsule.
  • the prebiotic fibre may be selected from the group consisting of inulin, oligofructose, lactose, resistant starch, fructooligosaccharides (FOS), galactooligosaccharides (GOS), transgalactooligosaccharides (TOS), xylooligosaccharides (XOS), polydextrose, wheat dextrin, acacia gum, psyllium, banana, whole grain wheat, and whole grain corn.
  • FOS fructooligosaccharides
  • GOS galactooligosaccharides
  • TOS transgalactooligosaccharides
  • XOS xylooligosaccharides
  • the prebiotic fibre may be selected from the group consisting of inulin, oligofructose, resistant starch, fructooligosaccharides (FOS), galactooligosaccharides (GOS), transgalactooligosaccharides (TOS), xylooligosaccharides (XOS), polydextrose, wheat dextrin, acacia gum, psyllium, banana, whole grain wheat, and whole grain corn.
  • the prebiotic fibre may be inulin or an oligosaccharide.
  • the prebiotic fibre may be inulin or an oligosaccharide selected from the group consisting of FOS, GOS, TOS, and XOS.
  • the prebiotic fibre may be selected from the group consisting of inulin, FOS, GOS, TOS, and XOS.
  • the prebiotic fibre is inulin.
  • the prebiotic fibre such as inulin may be mixed with a dairy product such as yoghurt.
  • the prebiotic fibre is a blend of inulin and yoghurt.
  • the first soft capsule comprises a blend of inulin and yoghurt.
  • Yoghurtene Balance CQ with product number 6099946 (Givaudan UK Ltd., Ashford, UK).
  • Yoghurtene contains whey proteins, lactose, lactic acid, vitamins A, vitamins B, and minerals.
  • Yoghurtene has low fat content.
  • Yoghurtene does not contain casein proteins.
  • the first soft capsule may comprise the prebiotic fibre, such as a blend of inulin and yoghurt, in an amount of 0.01 to 10 parts by weight based on 100 parts by weight of the first soft capsule.
  • the first soft capsule may comprise the prebiotic fibre, such as a blend of inulin and yoghurt, in an amount of 0.01 to 5 parts by weight, 0.05 to 5 parts by weight, 0.1 to 2 parts by weight, 0.1 to 1 parts by weight, or 0.5 to 1 parts by weight based on 100 parts by weight of the first soft capsule.
  • the first soft capsule may comprise one or more active ingredients capable of blocking adhesion of harmful bacteria to the oral cavity, a zinc salt, and a prebiotic fibre.
  • the first soft capsule may comprise one or more active ingredients capable of blocking adhesion of harmful bacteria to the oral cavity, a zinc salt, and a prebiotic fibre, wherein the one or more active ingredients capable of blocking adhesion of harmful bacteria to the oral cavity are selected from the group consisting of cranberry extract, wild blueberry extract, strawberry extract, tea tree oil, and chamomile oil.
  • the second soft capsule may comprise one or more active ingredients capable of blocking adhesion of harmful bacteria to the stomach and an alginate, wherein the one or more active ingredients capable of blocking adhesion of harmful bacteria to the stomach are selected from the group consisting of cranberry extract, wild blueberry extract, strawberry extract, tea tree oil, chamomile oil, tea extract, neem stick extract, snowdrop extract, seaweed extract, hop bract extract, Galla chinensis extract, avocado, and legume storage proteins
  • the present invention provides a soft capsule comprising (a) a first soft capsule configured for targeted delivery to the mouth and (b) a second soft capsule configured for targeted delivery to the stomach, wherein the first soft capsule comprises one or more active ingredients capable of blocking adhesion of harmful bacteria to the oral cavity, a zinc salt, and a prebiotic fibre, wherein the one or more active ingredients capable of blocking adhesion of harmful bacteria to the oral cavity are selected from the group consisting of cranberry extract, wild blueberry extract, strawberry extract, tea tree oil, and chamomile oil; the second soft capsule comprises one or more active ingredients capable of blocking adhesion of harmful bacteria to the stomach and an alginate, wherein the one or more active ingredients capable of blocking adhesion of harmful bacteria to the stomach are selected from the group consisting of cranberry extract, wild blueberry extract, strawberry extract, tea tree oil, chamomile oil, tea extract, neem stick extract, snowdrop extract, seaweed extract, hop bract extract, Galla chinensis extract,
  • the first soft capsule may comprise a cranberry extract, a zinc salt, and a prebiotic fibre.
  • the first soft capsule may comprise a cranberry extract, a zinc acetate, and a blend of inulin and yoghurt.
  • the second soft capsule may comprise, consist essentially of, or consist of the active ingredients having an effect in the stomach. In certain embodiments, the second soft capsule may comprise, consist essentially of, or consist of an active ingredient capable of blocking adhesion of harmful bacteria to the stomach and an alginate.
  • an active ingredient capable of blocking adhesion of harmful bacteria to the stomach includes the wording "one or more active ingredients capable of blocking adhesion of harmful bacteria to the stomach”.
  • the second soft capsule may comprise, consist essentially of, or consist of one or more active ingredients capable of blocking adhesion of harmful bacteria to the stomach and an alginate.
  • the alginate may be selected from the group consisting of sodium alginate, potassium alginate, and calcium alginate.
  • the alginate is sodium alginate.
  • Sodium alginate is a gum, extracted from the cell walls of brown algae.
  • the second soft capsule may comprise the alginate, such as sodium alginate, in an amount of 1 to 50 parts by weight based on 100 parts by weight of the second soft capsule.
  • the second soft capsule may comprise the alginate, such as sodium alginate, in an amount of 1 to 25 parts by weight, 1 to 10 parts by weight, or 1 to 5 parts by weight based on 100 parts by weight of the second soft capsule
  • the second soft capsule may comprise a cranberry extract and an alginate. In certain embodiments, the second soft capsule may comprise a cranberry extract and sodium alginate.
  • the first soft capsule may further comprise an edible vegetable oil.
  • the edible vegetable oil allows to control the flavour and/or to improve the stability of the first soft capsule as taught herein and/or functions as a solvent and/or functions as a carrier.
  • the vegetable oil as defined herein may be one or more of tea tree oil, palm oil, sunflower oil, safflower oil, sesame oil, rapeseed oil, and grape-seed oil.
  • the first soft capsule may comprise the edible vegetable oil in an amount of 0 to 99 parts by weight based on 100 parts by weight of the first soft capsule.
  • the first soft capsule may comprise an active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity, a metal salt, a prebiotic fibre, and an edible vegetable oil.
  • the first soft capsule may comprise an active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity, a zinc salt, a prebiotic fibre, and an edible vegetable oil.
  • the first soft capsule may also comprise a flavouring component.
  • the flavouring component may be mint flavour, spearmint flavour, strawberry flavour, vanilla flavour, cinnamon flavour, and/or citrus flavour.
  • the first soft capsule may comprise the flavouring component in an amount of 0.01 to 50 parts by weight based on 100 parts by weight of the first soft capsule.
  • the first soft capsule may comprise an active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity, a metal salt, a prebiotic fibre, and a flavouring component.
  • the first soft capsule may comprise an active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity, a zinc salt, a prebiotic fibre, and a flavouring component.
  • the first soft capsule may comprise an active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity, a metal salt, a prebiotic fibre, an edible vegetable oil, and a flavouring component.
  • the first soft capsule may comprise an active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity, a zinc salt, a prebiotic fibre, an edible vegetable oil, and a flavouring component.
  • the flavouring component may be a sweetening, an acidulant, and a bitter flavouring.
  • An example of the sweetening may be aspartame, stevia, saccharin sodium, or thaumatin.
  • An example of the acidulant may be citric acid, malic acid, tartaric acid, or fumaric acid.
  • An example of the bitter flavouring may be caffeine or naringin.
  • the first soft capsule may comprise at least one flavouring component selected from the sweetening, the acidulant, and the bitter flavouring.
  • the first soft capsule may further comprise a colorant and/or an aroma.
  • the colorant and aroma may be as known in the art.
  • the first soft capsule may comprise the colorant and/or the aroma in an amount not more than 80 parts by weight based on 100 parts by weight of the first soft capsule.
  • the first soft capsule may comprise an active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity, a metal salt, a prebiotic fibre, and a colorant and/or an aroma.
  • the first soft capsule may comprise an active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity, a zinc salt, a prebiotic fibre, and a colorant and/or an aroma.
  • the first soft capsule may comprise an active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity, a metal salt, a prebiotic fibre, an edible vegetable oil, a flavouring component, and a colorant and/or an aroma.
  • the second soft capsule may further comprise an edible vegetable oil as defined herein.
  • the edible vegetable oil allows to control the flavour and/or to improve the stability of the second soft capsule as taught herein and/or functions as a solvent and/or functions as a carrier.
  • the second soft capsule may comprise the edible vegetable oil in an amount of 0 to 99 parts by weight based on 100 parts by weight of the second soft capsule.
  • the second soft capsule may comprises an active ingredient capable of blocking adhesion of harmful bacteria to the stomach, an alginate, and an edible vegetable oil.
  • the second soft capsule may further comprise a colorant and/or an aroma, as defined herein.
  • a total amount of the colorant and/or the aroma formulated in the second soft capsule may preferably be not more than 80 parts by weight based on 100 parts by weight of the second soft capsule.
  • the second soft capsule may comprises an active ingredient capable of blocking adhesion of harmful bacteria to the stomach, an alginate, and a colorant and/or an aroma.
  • the second soft capsule may comprises an active ingredient capable of blocking adhesion of harmful bacteria to the stomach, an alginate, an edible vegetable oil, and a colorant and/or an aroma.
  • the second soft capsule may comprises an active ingredient capable of blocking adhesion of harmful bacteria to the stomach, an alginate, and optionally an edible vegetable oil, a colorant, and/or an aroma.
  • the first and/or second soft capsule may further comprise one or more pharmaceutical excipients.
  • suitable pharmaceutical excipients depend on the dosage form and identities of the active ingredients and can be selected by the skilled person (e.g. by reference to the Handbook of Pharmaceutical Excipients 6 th Edition 2009, eds. Rowe et al.).
  • carrier or “excipient” includes any and all solvents, diluents, buffers (such as neutral buffered saline or phosphate buffered saline), solubilisers, colloids, dispersion media, vehicles, fillers, chelating agents (such as EDTA or glutathione), amino acids (such as glycine), proteins, disintegrants, binders, lubricants, wetting agents, emulsifiers, sweeteners, colorants, flavourings, aromatisers, thickeners, agents for achieving a depot effect, coatings, antifungal agents, preservatives, stabilisers, antioxidants, tonicity controlling agents, absorption delaying agents, and the like.
  • chelating agents such as EDTA or glutathione
  • amino acids such as glycine
  • proteins disintegrants
  • binders such as EDTA or glutathione
  • lubricants such as glycine
  • wetting agents such as glycine
  • the first and/or second soft capsule may comprise pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions, such as pH adjusting and buffering agents, preservatives, complexing agents, tonicity adjusting agents, wetting agents and the like, for example, sodium acetate, sodium lactate, sodium phosphate, sodium hydroxide, hydrogen chloride, benzyl alcohol, parabens, EDTA, sodium oleate, sodium chloride, potassium chloride, calcium chloride, sorbitan monolaurate, triethanolamine oleate, etc.
  • the first and/or second soft capsule may further comprise one or more compounds selected from the group consisting of plant extracts, vitamins, minerals, amino acids, and enzymes.
  • the weight of the first soft capsule or outer capsule is from 100 mg to 300 mg.
  • the weight of the first soft capsule or outer capsule is from 200 mg to 300 mg, from 220 mg to 300 mg, from 220 mg to 280 mg, from 230 mg to 290 mg, or from 235 mg to 287 mg.
  • the weight of the first soft capsule or outer capsule is about 261 mg (e.g., 261 mg ⁇ 26 mg).
  • weight of the first soft capsule can be used interchangeably and refers to the (total) weight of the soft capsule.
  • weight refers to the average weight.
  • the average weight can be determined by weighing 20 capsules or beads with an electric balance and dividing the result by 20. Typically, every capsule or bead is weighted 3 times.
  • the first soft capsule may comprise from 1 mg to 150 mg by weight of the cranberry extract, from 1 mg to 10 mg by weight of zinc salt, and from lmg to 10 mg by weight of prebiotic fibre. In certain embodiments, the first soft capsule may comprises from 1 mg to 150 mg by weight of cranberry extract, from 1 mg to 10 mg by weight of zinc acetate, and from lmg to 10 mg by weight of a blend of inulin and yoghurt.
  • the weight of the second soft capsule or inner capsule is from 5 mg to 50 mg.
  • the weight of the second soft capsule or outer capsule is from 10 mg to 40 mg, from 20 mg to 40 mg, from 25 mg to 45 mg, from 25 mg to 40 mg, from 25 mg to 35 mg, from 30 mg to 40 mg, or from 30mg to 38 mg.
  • the weight of the second soft capsule or inner capsule is about 34 mg (e.g., 34 mg ⁇ 4 mg).
  • weight of the second soft capsule can be used interchangeably and refers to the (total) weight of the second soft capsule.
  • the second soft capsule may comprise from 1 mg to 15 mg by weight of the cranberry extract and from 1 mg to 15 mg by weight of the alginate.
  • the diameter of the first soft capsule may be from 2.0 mm to 12.0 mm.
  • the diameter of the first soft capsule may be from 4.0 mm to 10.0 mm or from 6.0 mm to 10.0 mm.
  • the diameter of the first soft capsule is about 8.0 mm (e.g., 8.0 mm ⁇ 0.2 mm).
  • diameter refers to the average diameter.
  • the average diameter can be determined by measuring 20 capsules or beads in line with ruler and dividing the result by 20. Typically, every capsule or bead is measured 3 times.
  • the diameter of the second soft capsule may be from 0.5 mm to 6.0 mm.
  • the diameter of the second soft capsule may be from 1.0 mm to 6.0 mm, from 2.0 to 6.0 mm, or from 3.0 to 5.0 mm.
  • the diameter of the second soft capsule is about 4.0 mm (e.g., 4.0 mm ⁇ 0.2 mm).
  • diameter of the second soft capsule can be used interchangeably and refers to the diameter of the second soft capsule.
  • the soft capsule as taught herein may comprise a first soft capsule composed of a first soft capsule layer and a first soft capsule content, and a second soft capsule composed of a second soft capsule layer and a second soft capsule content.
  • the soft capsule as taught herein is a multi-layered soft capsule or capsule- in-capsule comprising a first soft capsule composed of a first soft capsule layer and a first soft capsule content, and a second soft capsule composed of a second soft capsule layer and a second soft capsule content.
  • the multi-layered structure or capsule-in-capsule structure of the soft capsule as taught herein allows a first release in the oral cavity of the active ingredients having an effect in the oral cavity followed by a second release in the stomach of the active ingredients having an effect in the stomach.
  • the release in the oral cavity of the active ingredients having an effect in the oral cavity following by a release in the stomach of the active ingredients having an effect in the stomach allows treating halitosis effectively both instantly and in the long term.
  • the soft capsule as taught herein comprises or consists of four layers.
  • the four layers can be referred to, from the outside to the inside of the capsule, as a first soft capsule layer (or outer layer), a first soft capsule content (or outer content), second soft capsule layer (or inner layer), and second soft capsule content (or inner content).
  • the soft capsule as taught herein comprises a first soft capsule and a second soft capsule encapsulated in the first soft capsule.
  • the first soft capsule is composed of a first soft capsule layer and a first soft capsule content containing the active ingredients having an effect in the oral cavity, wherein the first soft capsule content is encapsulated in the first soft capsule layer.
  • the second soft capsule is composed of a second soft capsule layer and a first soft capsule content containing the active ingredients having an effect in the stomach, wherein the second soft capsule content is encapsulated in the second soft capsule layer.
  • active ingredients having an effect in the oral cavity refers to (the combination of) at least an active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity, a metal salt, and a prebiotic fibre.
  • active ingredients having an effect in the stomach refers to (the combination of) at least an active ingredient capable of blocking adhesion of harmful bacteria to the stomach and an alginate.
  • the first soft capsule layer comprises a metal salt as defined herein, preferably a zinc salt, more preferably zinc acetate.
  • the first soft capsule layer comprises a metal salt as defined herein, preferably a zinc salt, more preferably zinc acetate; and a base material such as gelatine, agar, methylcellulose, hypromellose or hydroxypropylmethylcellulose (HPMC), or a mixture of any two or more thereof, preferably gelatine.
  • the first soft capsule layer comprises a zinc salt and gelatine.
  • the first soft capsule layer comprises zinc acetate and gelatine.
  • the second soft capsule layer comprises an active ingredient capable of blocking adhesion of harmful bacteria to the stomach, preferably a cranberry extract, and an alginate, preferably sodium alginate.
  • the second soft capsule layer comprises an active ingredient capable of blocking adhesion of harmful bacteria to the stomach, an alginate; and a base material such as gelatine, agar, methylcellulose, hypromellose or HPMC, or a mixture of any two or more thereof, preferably gelatine.
  • the second soft capsule layer comprises a cranberry extract, sodium alginate, and a base material such as gelatine, agar, methylcellulose, hypromellose or HPMC, or a mixture of any two or more thereof, preferably gelatine.
  • the second soft capsule layer comprises a cranberry extract, sodium alginate, and gelatine.
  • the first and second soft capsule layer may comprise a base material.
  • the base material for forming the first and second soft capsule layer may be any material capable of forming a soft capsule layer such as gelatine, agar, methylcellulose, hypromellose or HPMC, or a mixture of any two or more thereof.
  • the material for forming the first and second soft capsule layers of a multi-layered soft capsule as taught herein may also comprise a water-soluble polyol such as sorbitol, glycerine and the like, sodium alginate or low methoxyl pectin or one obtained by gelling an aqueous solution of sodium alginate or low methoxyl pectin with a polyvalent ion, preferably bi- or more valent ion or the like.
  • a water-soluble polyol such as sorbitol, glycerine and the like, sodium alginate or low methoxyl pectin or one obtained by gelling an aqueous solution of sodium alginate or low methoxyl pectin with a polyvalent ion, preferably bi- or more valent ion or the like.
  • the polyvalent ion can be a salt of polyvalent metal such as bi- or more valent metal, particularly when gelling the aqueous solution of sodium alginate, a water-soluble calcium salt, such as calcium chlorate, calcium phosphate and the like is suitably used, or when gelling low methoxyl pectin, a water-soluble salt, such as calcium, magnesium or the like is suitably used.
  • the material for forming the first and second soft capsule layers may further contain a flavouring component as defined herein.
  • the flavouring component may be a sweetening, an acidulant, and a bitter flavouring.
  • An example of the sweetening may be aspartame, stevia, saccharin sodium, or thaumatin.
  • An example of the acidulant may be citric acid, malic acid, tartaric acid, or fumaric acid.
  • An example of the bitter flavouring may be caffeine or naringin.
  • the first soft capsule layer and/or the second soft capsule layer may comprise at least one flavouring component selected from the sweetening, the acidulant, and the bitter flavouring.
  • the material for forming the first and second soft capsule layers of the soft capsules as taught herein may further comprise an adjuvant selected from the group consisting of a plasticizer, a preservative, a colorant, and an aroma.
  • the total amount of the adjuvant and the flavouring component formulated in the material for forming the first and second soft capsule layers may be 0.1 to 50 parts by weight, based on 100 parts by weight of the material for forming the first and second soft capsule layers.
  • the flavouring component may be in an amount of 0.1 to 30 parts by weight based on 100 parts by weight of the material.
  • the material for forming the second soft capsule layers may further comprise a substance such as agar or gum Arabic.
  • the second soft capsule layers may further comprise a substance such as agar or gum Arabic in an amount of 0.01 to 10% by weight based on the total amount of the adjuvant.
  • the first soft capsule content may comprise an active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity and a prebiotic fibre.
  • the first soft capsule content may further comprise an edible vegetable oil as defined herein.
  • the edible vegetable oil allows to control the flavour and to improve the stability of the soft capsule as taught herein and/or functions as a solvent and/or functions as a carrier.
  • the first soft capsule content may comprise the edible vegetable oil in an amount of 0 to 99 parts by weight based on 100 parts by weight of the content.
  • the first soft capsule content may also comprise a flavouring component as described herein.
  • the first soft capsule content may comprise the flavouring component in an amount of 0.01 to 50 parts by weight based on 100 parts by weight of the first soft capsule content.
  • the first soft capsule content may further comprise a colorant and/or an aroma, as defined herein.
  • the first soft capsule content may comprise the colorant and/or the aroma in an amount not more than 80 parts by weight based on 100 parts by weight of the first soft capsule content.
  • the second soft capsule content may comprise, consist essentially of, or consist of an active ingredient capable of blocking adhesion of harmful bacteria to the stomach.
  • the second soft capsule content may also comprise an edible vegetable oil, a colorant, and/or an aroma, as defined herein.
  • the second soft capsule content may comprise the edible vegetable oil in an amount of 0 to 99 parts by weight based on 100 parts by weight of the second soft capsule content.
  • a total amount of the colorant and/or the aroma formulated in the second soft capsule content may preferably be not more than 80 parts by weight based on 100 parts by weight of the second soft capsule content.
  • a total amount of the first and second soft capsule contents may be 10% to 95% by weight, preferably 50% to 90% by weight, based on the total weight of the soft capsule.
  • the soft capsule is configured for oral administration.
  • the soft capsules as taught herein may be gelatine capsules (i.e., capsulae gelatinosae), also referred to as gel caps or gelcaps.
  • the soft capsules as taught herein may be vegetable or vegetarian capsules. Examples of vegetarian capsules are Vegicaps® (Catalent Pharma Solutions, Somerset, USA) or Vcaps® Plus capsules (Capsugel, Bornem, Belgium).
  • the soft capsules as taught herein may advantageously be used as dietary supplements or medical devices.
  • a further aspect relates to the use of the soft capsules as taught herein as a dietary supplement or a medical device.
  • a further aspect relates to the soft capsules as taught herein for use as a medicament.
  • a further aspect relates to the soft capsules as taught herein for use as a medicinal product.
  • the present invention provides the soft capsules as taught herein for use in the treatment (including throughout the present specification therapeutic and/or preventative measures) of halitosis.
  • the present invention provides a soft capsule comprising (a) a first soft capsule configured for targeted delivery to the mouth and (b) a second soft capsule configured for targeted delivery to the stomach, wherein the first soft capsule comprises an active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity, a metal salt, and a prebiotic fibre; the second soft capsule comprises an active ingredient capable of blocking adhesion of harmful bacteria to the stomach and an alginate; and the second soft capsule is contained in the first soft capsule, for use in the treatment of halitosis.
  • the present invention provides a soft capsule for use in the treatment of halitosis, wherein the soft capsule comprises (a) a first soft capsule configured for targeted delivery to the mouth and (b) a second soft capsule configured for targeted delivery to the stomach, wherein the first soft capsule comprises one or more active ingredients capable of blocking adhesion of harmful bacteria to the oral cavity, a zinc salt, and a prebiotic fibre, wherein the one or more active ingredients capable of blocking adhesion of harmful bacteria to the oral cavity are selected from the group consisting of cranberry extract, wild blueberry extract, strawberry extract, tea tree oil, and chamomile oil; the second soft capsule comprises one or more active ingredients capable of blocking adhesion of harmful bacteria to the stomach and an alginate, wherein the one or more active ingredients capable of blocking adhesion of harmful bacteria to the stomach are selected from the group consisting of cranberry extract, wild blueberry extract, strawberry extract, tea tree oil, chamomile oil, tea extract, neem stick extract, snowdrop extract, seaweed extract, hop
  • soft capsules as taught herein in the treatment of halitosis are advantageous inter alia because these soft capsules allow efficient treatment during longer periods due to the combined action of the active ingredients in the mouth and in the stomach.
  • a further advantage of the present soft capsules is that they also have an instant effect without any side effects.
  • any one of the soft capsules as taught herein for the manufacture of a medicament for the treatment of halitosis.
  • a soft capsule comprising (a) a first soft capsule configured for targeted delivery to the mouth and (b) a second soft capsule configured for targeted delivery to the stomach, wherein the first soft capsule comprises an active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity, a metal salt, and a prebiotic fibre; the second soft capsule comprises an active ingredient capable of blocking adhesion of harmful bacteria to the stomach and an alginate; and the second soft capsule is contained in the first soft capsule, for the manufacture of a medicament for the treatment of halitosis.
  • a soft capsule for the manufacture of a medicament for the treatment of halitosis
  • the soft capsule comprises (a) a first soft capsule configured for targeted delivery to the mouth and (b) a second soft capsule configured for targeted delivery to the stomach
  • the first soft capsule comprises one or more active ingredients capable of blocking adhesion of harmful bacteria to the oral cavity, a zinc salt, and a prebiotic fibre
  • the one or more active ingredients capable of blocking adhesion of harmful bacteria to the oral cavity are selected from the group consisting of cranberry extract, wild blueberry extract, strawberry extract, tea tree oil, and chamomile oil
  • the second soft capsule comprises one or more active ingredients capable of blocking adhesion of harmful bacteria to the stomach and an alginate, wherein the one or more active ingredients capable of blocking adhesion of harmful bacteria to the stomach are selected from the group consisting of cranberry extract, wild blueberry extract, strawberry extract, tea tree oil, chamomile oil, tea extract, neem stick extract, snowdrop extract, seaweed
  • a method for treating halitosis in a subject in need of such treatment, comprising administering to said subject any one of the soft capsules as taught herein.
  • a method for treating halitosis in a subject in need of such treatment comprising administering to said subject a therapeutically or prophylactically effective amount of a soft capsule comprising (a) a first soft capsule configured for targeted delivery to the mouth and (b) a second soft capsule configured for targeted delivery to the stomach, wherein the first soft capsule comprises an active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity, a metal salt, and a prebiotic fibre; the second soft capsule comprises an active ingredient capable of blocking adhesion of harmful bacteria to the stomach and an alginate; and the second soft capsule is contained in the first soft capsule.
  • a method for treating halitosis in a subject in need of such treatment comprising administering to said subject a therapeutically or prophylactically effective amount of a soft capsule comprising (a) a first soft capsule configured for targeted delivery to the mouth and (b) a second soft capsule configured for targeted delivery to the stomach, wherein the first soft capsule comprises one or more active ingredients capable of blocking adhesion of harmful bacteria to the oral cavity, a zinc salt, and a prebiotic fibre, wherein the one or more active ingredients capable of blocking adhesion of harmful bacteria to the oral cavity are selected from the group consisting of cranberry extract, wild blueberry extract, strawberry extract, tea tree oil, and chamomile oil; the second soft capsule comprises one or more active ingredients capable of blocking adhesion of harmful bacteria to the stomach and an alginate, wherein the one or more active ingredients capable of blocking adhesion of harmful bacteria to the stomach are selected from the group consisting of cranberry extract, wild blueberry extract, strawberry extract, tea tree oil, chamomile oil, tea extract
  • Such method of treatment typically involves oral administration of the soft capsules.
  • halitosis can be used interchangeably and refer to a disorder in which a noticeably unpleasant odour is present on the exhaled breath.
  • halitosis is potentially the sum of these types in any combination, superimposed on the physiologic odour present in all healthy individuals.
  • the treatment of halitosis comprises an oral treatment of halitosis and a gastrointestinal treatment of halitosis.
  • the combined treatment of the oral cavity and the gastrointestinal tract, in particular the stomach allows an effective treatment of halitosis with an immediate effect after administration of the soft capsules as taught herein and a long-term effect.
  • oral treatment of halitosis refers to a treatment of halitosis in the oral cavity.
  • gastrointestinal treatment of halitosis refers to a treatment of halitosis in the gastrointestinal tract, in particular in the stomach.
  • the gastrointestinal treatment of halitosis may comprise a treatment of halitosis in the stomach.
  • the active ingredients having an effect in the stomach advantageously neutralize harmful bacteria in the stomach by blocking bacterial adhesion to the mucosa of the stomach and form a protective layer on the content of the stomach, thereby advantageously resulting in a long-term treatment of halitosis.
  • the terms “subject” or “patient” can be used interchangeably and refer to animals, preferably warm-blooded animals, more preferably vertebrates, even more preferably mammals, still more preferably primates, and specifically includes human patients and non-human mammals and primates.
  • Preferred subjects are human subjects.
  • the term “mammal” includes any animal classified as such, including, but not limited to, humans, domestic and farm animals, zoo animals, sport animals, pet animals, companion animals and experimental animals, such as, for example, mice, rats, hamsters, rabbits, dogs, cats, guinea pigs, cattle, cows, sheep, horses, pigs and primates, e.g., monkeys and apes.
  • Particularly preferred are human subjects, including both genders and all age categories thereof.
  • a phrase such as "a subject in need of treatment” includes subjects that would benefit from treatment of a given condition, particularly halitosis. Such subjects may include, without limitation, those that have been diagnosed with said condition, those prone to develop said condition and/or those in who said condition is to be prevented.
  • treat or “treatment” encompass both the therapeutic treatment of an already developed disease or condition, such as the therapy of an already developed halitosis, as well as prophylactic or preventive measures, wherein the aim is to prevent or lessen the chances of incidence of an undesired affliction, such as to prevent occurrence, development and progression of halitosis.
  • beneficial or desired clinical results may include, without limitation, alleviation of one or more symptoms, diminishment of extent of disease, and the like.
  • prophylactically effective amount refers to an amount of an active ingredient or pharmaceutical agent that inhibits or delays in a subject the onset of a disorder as being sought by a researcher, veterinarian, medical doctor or other clinician.
  • therapeutically effective amount refers to an amount of active ingredient or pharmaceutical agent that elicits the biological or medicinal response in a subject that is being sought by a researcher, veterinarian, medical doctor or other clinician, which may include inter alia alleviation of the symptoms of the disease or condition being treated. Methods are known in the art for determining therapeutically and prophylactically effective doses for the active ingredients as taught herein.
  • a further aspect provides a method for preparing a soft capsule as taught herein, such as a soft capsule for treating halitosis, comprising simultaneously extruding a composite jet stream into a cooling solution, wherein the composite jet stream consists of a second soft capsule filling solution extruded through a first nozzle, a second soft capsule layer-forming solution though a second nozzle, a first soft capsule filling solution extruded through a third nozzle and a first soft capsule layer-forming solution extruded through a fourth nozzle, with the first, second, third and fourth nozzles being arranged concentrically, a diameter of the nozzles gradually increasing in a numerical order, and wherein the first soft capsule layer-forming solution comprises a metal salt, the first soft capsule filling solution comprises an active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity and a prebiotic fibre, the second soft capsule layer-forming solution comprises an alginate, and the second soft capsule filling solution comprises an active ingredient capable of blocking adhesion of harmful bacteria to
  • the invention provides a method for preparing a soft capsule as taught herein, comprising simultaneously extruding a composite jet stream into a cooling solution, wherein the composite jet stream consists of a second soft capsule filling solution extruded through a first nozzle, a second soft capsule layer-forming solution though a second nozzle, a first soft capsule filling solution extruded through a third nozzle and a first soft capsule layer-forming solution extruded through a fourth nozzle, with the first, second, third and fourth nozzles being arranged concentrically, a diameter of the nozzles gradually increasing in a numerical order, and wherein the first soft capsule layer- forming solution comprises a metal salt, wherein the metal salt is a zinc salt; the first soft capsule filling solution comprises one or more active ingredients capable of blocking adhesion of harmful bacteria to the oral cavity and a prebiotic fibre, wherein the one or more active ingredients capable of blocking adhesion of harmful bacteria to the oral cavity are selected from the group consisting of cranberry extract,
  • the methods as taught herein may comprise the prior step of preparing the first soft capsule layer-forming solution by mixing a metal salt, preferably a zinc salt, more preferably zinc acetate; and a base material such as gelatine, agar, methylcellulose, HPMC, or a mixture of any two or more thereof, preferably gelatine.
  • the methods as taught herein may comprise the prior step of preparing the first soft capsule layer- forming solution by mixing a zinc salt and gelatine.
  • the methods as taught herein may comprise the prior step of preparing the first soft capsule layer-forming solution by mixing zinc acetate and gelatine.
  • the methods as taught herein may comprise the prior step of preparing the first soft capsule filling solution by mixing an active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity and a prebiotic fibre. In certain embodiments, the methods as taught herein may comprise the prior step of preparing the first soft capsule filling solution by mixing an active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity, a prebiotic fibre, and an edible vegetable oil. In certain embodiments, the methods as taught herein may further comprise the prior step of preparing the first soft capsule filling solution by mixing an active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity, a prebiotic fibre, an edible vegetable oil, and a flavouring component.
  • the methods as taught herein may further comprise the prior step of preparing the first soft capsule filling solution by mixing an active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity, a prebiotic fibre, an edible vegetable oil, a flavouring component, and a colorant and/or an aroma.
  • the methods as taught herein may further comprise the prior step of preparing the first soft capsule filling solution by mixing an active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity, a prebiotic fibre, and optionally an edible vegetable oil, a flavouring component, a colorant, and/or aroma.
  • the methods as taught herein may comprise the prior step of preparing the second soft capsule layer-forming solution by mixing an active ingredient capable of blocking adhesion of harmful bacteria to the stomach, an alginate, and a base material such as gelatine, agar, methylcellulose, hypromellose or HPMC, or a mixture of any two or more thereof.
  • the methods as taught herein may comprise the prior step of preparing the second soft capsule layer-forming solution by mixing a cranberry extract, sodium alginate, and a base material such as gelatine, agar, methylcellulose, hypromellose or HPMC, or a mixture of any two or more thereof, preferably gelatine.
  • the methods as taught herein may comprise the prior step of preparing the second soft capsule layer-forming solution by mixing a cranberry extract, sodium alginate, and gelatine.
  • the methods as taught herein may comprise the prior step of preparing the second soft capsule filling solution by mixing an active ingredient capable of blocking adhesion of harmful bacteria to the stomach, and an edible vegetable oil. In certain embodiments, the methods as taught herein may comprise the prior step of preparing the second soft capsule filling solution by mixing an active ingredient capable of blocking adhesion of harmful bacteria to the stomach, an edible vegetable oil, and a colorant and/or an aroma. In certain embodiments, the methods as taught herein may comprise the prior step of preparing the second soft capsule filling solution by mixing an active ingredient capable of blocking adhesion of harmful bacteria to the stomach, and optionally an edible vegetable oil, a colorant, and/or an aroma.
  • the soft capsule as taught herein as a final product may be obtained by drying the resulting capsule produced by the above method.
  • a method for preparing or producing a soft capsule as taught herein may comprise preparing a sheet for the second soft capsule layer comprising a material capable of forming a soft capsule layer as the base, an active ingredient capable of blocking adhesion of harmful bacteria to the stomach, and an alginate, and drying to obtain a dried sheet; encapsulating the second soft capsule content comprising an active ingredient capable of blocking adhesion of harmful bacteria to the stomach with the dried sheet on a rotary filler to form the second soft capsule; and on a rotary filler, simultaneously encapsulating both the second soft capsule and the first soft capsule comprising an active ingredient capable of blocking adhesion of harmful bacteria to the oral cavity, and a prebiotic fibre with a sheet for the first soft capsule layer preliminary prepared and dried, wherein the sheet for the first soft capsule comprises a material capable of forming a soft capsule layer as the base and a metal salt.
  • the material capable of forming a soft capsule layer may be gelatine, agar, methylcellulose, hypromellose or hydroxypropylmethylcellulose (HPMC), or a mixture of any two or more thereof.
  • the encapsulation process may be easily performed by adequately vibrating the composite jet stream with a vibration mean to readily release the jet stream, and thereby a particle size of the resulting capsules may be controlled uniformly.
  • the first soft capsule may be formed into a particle size in a diameter of 2.0 to 12 mm, preferably 8 mm.
  • the second soft capsule may be formed into a particle size in diameter of 0.5 mm to 6 mm, preferably 4 mm.
  • Example 1 Soft capsule according to an embodiment of the present invention
  • Table 1 lists the ingredients and the amount of each ingredient in a first soft capsule according to an embodiment of the present invention.
  • Table 2 lists the ingredients and the amount of each ingredient in a second soft capsule according to an embodiment of the present invention.
  • Table 1 First soft capsule (i.e., outer capsule) according to an embodiment of the present invention
  • a soft capsule according to an embodiment of the present invention can be obtained as follows.
  • a first soft capsule layer-forming solution and a second soft capsule layer-forming solution are prepared for the first soft capsule layer and the second soft capsule layer, respectively.
  • the first soft capsule layer which is a fast dissolve shell comprises zinc acetate and porcine gelatine.
  • the first soft capsule layer- forming solution is prepared by mixing zinc acetate and porcine gelatine.
  • the second soft capsule layer comprises cranberry extract, sodium alginate, and porcine gelatine.
  • the second soft capsule layer-forming solution is prepared by mixing cranberry extract, sodium alginate, and porcine gelatine.
  • a first soft capsule filing solution and a second soft capsule filling solution are prepared for the first soft capsule content and the second soft capsule content respectively.
  • the first soft capsule filing solution is prepared by mixing a cranberry extract, prebiotic fibre, mint flavour, and tea tree oil. Tea tree oil is used as a solvent and has advantageous anti-microbial effects.
  • the second soft capsule filing solution is prepared by mixing the cranberry extract and tea tree oil.
  • the second soft capsule filling solution is supplied into a first nozzle
  • the second soft capsule layer- forming solution is supplied into a second nozzle
  • the first soft capsule filling solution is supplied into a third nozzle
  • the first soft capsule layer-forming solution is supplied into an outermost fourth nozzle.
  • the first, second, third and fourth nozzles are arranged concentrically and the diameter of the nozzles gradually increases in a numerical order.
  • the multi-layered soft capsule according to an embodiment of the present invention is produced by simultaneously extruding the solutions through the annular ends of the nozzles, respectively, to make a four-phase composite jet stream, followed by releasing the jet stream into a cooling solution. The resulting soft capsule is then dried.
  • the soft capsules according to an embodiment of the present invention are spherical, light yellow colored gelatine capsules.
  • the weight of the second soft capsule layer is 8 mg.
  • the weight of the second soft capsule content is 26 mg.
  • the weight of the first soft capsule layer is 18 mg.
  • the weight of the first soft capsule content is 209 mg.
  • the weight of the second soft capsule according to an embodiment of the present invention is 34 mg ⁇ 4 mg.
  • the weight of the soft capsule according to an embodiment of the present invention is 261 mg ⁇ 26 mg.
  • the weight is the average weight as determined by weighing 20 capsules with an electric balance and dividing the result by 20. Averaging is performed after repeating 3 times.
  • the diameter of the second soft capsule according to an embodiment of the present invention is 4.0 mm ⁇ 0.2 mm.
  • the diameter of the (first) soft capsule according to an embodiment of the present invention is 8.0 mm ⁇ 0.2 mm.
  • the diameter is the average diameter as determined by measuring 20 capsules in line with a ruler and dividing the result by 20. Averaging is performed after repeating 3 times.
  • the total aerobic bacteria of the soft capsule according to an embodiment of the present invention are not more than 1000 CFU/g.
  • the soft capsules according to an embodiment of the present invention can be blistered.
  • the administration of a soft capsule according to an embodiment of the present invention can be one soft capsule per day to prevent and/or treat halitosis.
  • the administration of a soft capsule according to an embodiment of the present invention can be when the subject is in need of a treatment for instance after consuming certain foods (e.g., garlic or onion) or certain drinks (e.g., alcohol).
  • the soft capsules according to an embodiment of the present invention have a shelf life of 6 months from the date of manufacturing in case of storing at dry and cool place (e.g., below 25°C and 55% humidity). To ensure the viability and shelf life, it is recommended to store the soft capsules illustrating the present invention at refrigerated temperature in original sealed package.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Birds (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
PCT/EP2016/060492 2015-05-11 2016-05-11 Soft capsule and use in the treatment of halitosis WO2016180848A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP16725783.1A EP3294271B1 (en) 2015-05-11 2016-05-11 Soft capsule and use in the treatment of halitosis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BE2015/5294 2015-05-11
BE2015/5294A BE1022915B1 (nl) 2015-05-11 2015-05-11 Zachte capsule en gebruik in de behandeling van halitose

Publications (1)

Publication Number Publication Date
WO2016180848A1 true WO2016180848A1 (en) 2016-11-17

Family

ID=54011458

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2016/060492 WO2016180848A1 (en) 2015-05-11 2016-05-11 Soft capsule and use in the treatment of halitosis

Country Status (3)

Country Link
EP (1) EP3294271B1 (nl)
BE (1) BE1022915B1 (nl)
WO (1) WO2016180848A1 (nl)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2029697B1 (en) * 2021-11-09 2023-06-05 Univ Qilu Technology Blueberry popping boba prepared based on response surface method and preparation process thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1020177A1 (en) * 1997-09-10 2000-07-19 Morishita Jintan Co., Ltd. Multilayered soft capsule for eliminating foul breath and process for producing the same
WO2001019204A1 (en) * 1999-09-13 2001-03-22 Nabisco, Inc. Breath freshening comestible product

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1020177A1 (en) * 1997-09-10 2000-07-19 Morishita Jintan Co., Ltd. Multilayered soft capsule for eliminating foul breath and process for producing the same
US6426089B1 (en) 1997-09-10 2002-07-30 Morishita Jintan Co., Ltd. Multilayered soft capsule for eliminating bad breath and process for producing the same
WO2001019204A1 (en) * 1999-09-13 2001-03-22 Nabisco, Inc. Breath freshening comestible product

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DR VIDYA DODWAD ET AL: "P -46 International Journal of Pharma and Bio Sciences HERBAL MOUTHWASHES - A GIFT OF NATURE 1 DR. BHAVNA JHA KUKREJA AND 2 NATURAL CHEMISTRY RESEARCH ARTICLE", 1 June 2012 (2012-06-01), XP055201068, Retrieved from the Internet <URL:http://ijpbs.net/vol-3/issue-2/pharma/6.pdf> [retrieved on 20150708] *
MIYAZAKI ET AL., NIIGATA DENTAL JOURNAL, vol. 32, 1999, pages 7 - 11
ROWE ET AL.: "Handbook of Pharmaceutical Excipients", 2009
TANGERMAN; WINKEL, JOURNAL OF BREATH RESEARCH, vol. 4, no. 1, 2010

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2029697B1 (en) * 2021-11-09 2023-06-05 Univ Qilu Technology Blueberry popping boba prepared based on response surface method and preparation process thereof

Also Published As

Publication number Publication date
EP3294271B1 (en) 2020-07-01
EP3294271A1 (en) 2018-03-21
BE1022915B1 (nl) 2016-10-17

Similar Documents

Publication Publication Date Title
RU2405564C2 (ru) Способ применения экстракта гуавы и композиции, включающей экстракт гуавы
US20080057162A1 (en) Functionalized coffee
JP4653400B2 (ja) 糖尿病用組成物
US7776831B2 (en) Use of antifungal compositions to treat upper gastrointestinal conditions
JP5183104B2 (ja) 口臭除去用多重ソフトカプセル
MXPA02005486A (es) Composicion nutricional.
KR20000052950A (ko) 콜로이드성 염기성 구연산 비스머스를 포함하는 추잉검
US9585852B2 (en) Agmatine containing dietary supplements, nutraceuticals and foods
TW200843726A (en) Agent for relief or prevention of xerostomia
JP2008094754A (ja) 糖尿病または血糖コントロール用栄養組成物
US20120015021A1 (en) Anti-appetite adhesive compositions
JP5085131B2 (ja) 栄養補助食品、ならびにウマおよび他の動物における消化管潰瘍の治療および予防方法
US20240009171A1 (en) Compositions and methods for delivery of psilocin and prodrugs thereof
TW200950818A (en) Cysteine odor-reduced solid preparation
EP3758716A1 (en) Formulations treating acid reflux comprising sodium alginate
KR101790666B1 (ko) 애완동물용 구강용해필름
US6537543B1 (en) Intestinal activation food using natto powder
EP3294271B1 (en) Soft capsule and use in the treatment of halitosis
JP2007112795A (ja) アントラキノン系薬剤含有下剤医薬組成物
KR20040073039A (ko) 사료첨가제가 함유된 사료 및 그의 제조방법
CN112716969B (zh) 治疗阿尔茨海默症的组合物及其制备方法、应用
TW202308613A (zh) 用於抑制腎功能降低或改善腎功能之組成物
JP4610730B2 (ja) カルシウム補給用の組成物
EP4431091A1 (en) Composition with glycine for use treating insomnia disorder
JP2007145731A (ja) 止瀉効果を有する内服用製剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16725783

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE